Daiichi Sankyo Korea has reportedly completed submitting supplementary data as requested by the government regarding providing insurance benefits for its breast cancer treatment Enhertu, raising expectations about the issue’s re-discussion scheduled for May 3.

According to sources, the Korean offshoot of the Japanese pharma company completed the submission of complementary data to the Health Insurance Reviews and Assessment Service (HIRA) on Thursday last week.

HIRA failed to reach a conclusion on setting Enhertu’s reimbursement at its cancer disease deliberation meeting last month, requesting the company to supplement additional data and announce a re-discussion.

At last month’s meeting, the participants expressed concerns about the drug’s price and its effects on the insurance’s finance rather than showing the difference of views over its efficacy, forcing HIRA to ask the company to shoulder additional financial burdens.

“Metastatic breast cancer patients are still fighting every minute for their survival,” said a Daiichi Sankyo Korean official after HIRA decided to re-discuss the matter. “We are also going all out to gain time for even one more patient and secure insurance benefits for Enhertu.”

The supplementary data the company submitted reportedly included its offering of the price at the lowest level worldwide while considering taking an additional risk-sharing agreement (RSA).

Industry sources said the company had done almost all it could to help ease burdens on the insurance finance.

Enhertu drew attention last year with 50,000 consents to the National Assembly’s public petition calling for granting the domestic permit. Another petition urging to provide insurance benefits also drew 50,000 consents in three days, and the Assembly is examining the petition.

In the subcommittee to examine petitions on Tuesday, the calls for providing reimbursement for Enhertu were discussed, and the participants decided to “continue the review,” considering the issue will be re-discussed at the cancer disease deliberation committee.

The Assembly also recognizes the need for its insurance coverage and concluded there is a need to favorably consider applying positive reimbursements for patients, raising expectations about the result of the deliberation committee meeting.